Acydovir was evaluated as treatment of recurrent herpes simplex virus type 2 infection of the hand in a double-blind, placebo-controed crossover study. In nine fully evaluable patients, oral acyclovir (2 g/day in three doses for 10 days) initiated during the earlist phase of a recurrence reduced the mean durations (± standard deviation) of clinkal symptoms from 10.1 (±3.6) to 3.7 (±3.0) days (P = 0.008), signs from 11.1 (±3.7) to 6.2 (±3.3) days (P = 0.024), and viral positivity from 5.3 (+3.8) to 0.6 (±1.1) days (P = 0.011).
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Effective treatments for most human herpes simplex virus (HSV) infections have been well documented (7, (9) (10) (11) (12) . However, recurrent HSV infection of the band, which can be frequent, painful, and cosmetically unacceptable, has attracted little therapeutic attention (1-3, 5, 6, 8) . After an earlier uncontrolled observation, we evaluated in this double-blind, placebo-controlled crossover study the effects of early intervention with oral acyclovir on the durations of symptoms, signs, and virl culture positivity of recurrent HSV type 2 (HSV-2) infection of the hand (4) .
Fourteen patients (11 males and 3 females) with documented HSV-2 infection of the hand participated in a study that was approved by the University of Calgary Committee on Medical Bioethics. All the patients were between 18 and 50 years old and had between 2 and 12 recurrent infections per year. They were otherwise in good health with no evidence of any underlying immunodeficiency. All the females were using a recognized form of contraception and were not pregnant at the time of treatment.
A double-blind, placebo-controlled crossover design was adopted in view of the limited number of eligible patients. Due to uncertainties about the bioavailability of acyclovir at the time of the study design, a high-dose regimen was selected. Active drug or placebo (provided by Burroughs Weilcome, Kirkland, Quebec, Canada) was randomized to either cycle A or B by a computer program. The patients were given written instructions and a bottle of 100 tablets (cycle A). They were advised to take four tablets when prodromal symptoms which they felt likely to result in HSV infection of the hand were first noticed, followed by two doses each of three tablets in a 24-h period. A total of 10 tablets per day in three doses was given for a total of 10 days. The patients were reviewed within 24 h of initiating therapy and then daily until the episode resolved. After the first course of therapy, the patients returned the cycle A bottle and were given a second bottle (cycle B) with identical instructions.
The presence and severity of symptoms (pain, swelling, tingling, tenderness, and discomfort) and both local and systemic signs of infection (erythema, papule, vesicle, pustule, scab, lymphangitis, and lymphadenopathy) were recorded at each visit. 1.2 days (P = 0.003). For almost all patients, the duration of symptoms and time to symptomatic improvement were shorter during the acyclovir treatment than during the placebo treatment.
The mean duration of objective signs in the placebotreated group was 11.1 days, compared with 6.2 days in the acyclovir-treated group (P = 0.024). In every case, the duration of signs was shorter when the patients were receiving acyclovir therapy.
The mean difference in durations of viral shedding between the two study groups was statistically significant (5.3 versus 0.6 days; P = 0.011). Specimens from seven of the nine patients receiving therapy with oral acyclovir were not positive in viral culture. For two patients (12 and 6) , viral cultures were positive-at the initial and second visits only. In patient 13 during the placebo-treated episode, HSV was present from visits 1 to 9 and 11 to 15, representing what appeared clinically to be two recurrences in rapid succession.
In this study, a total daily dose of 2 g of oral acyclovir was found to be effective in reducing the durations of symptoms, signs, and viral positivity when initiated during the early sign of a recurrence of HSV-2 infection of the hand. However, the dosage of acyclovir, duration of therapy, and timing of intervention can likely be further optimized to give results equal or even superior to those described above. Other studies have suggested that lower doses of acyclovir are effective in the early treatment of recurrences of HSV-2 infections at other sites (10) . The 10-day course of therapy was chosen to be longer than the anticipated duration of a recurrence. Since acyclovir shortened the duration of an episode to around 5 days, a 10-day course of therapy appears to be excessive in most situations. It is also possible that earlier intervention during the prodromal phase of a recurrence may achieve greater clinical effects.
Although the vast majority of recurrent HSV infections of the hand are HSV-2, HSV-1 infection of the hand is occasionally recurrent (3) . Studies of recurrent HSV-1 infections of the lips suggest that they, too, respond to such treatment (9) . Unfortunately, due to the relative rarity of patients with such infections, controlled studies of HSV-1 infection of the hand may be impractical.
In summary, oral acyclovir administered during the early stages of recurrent HSV-2 infection of the hand had a beneficial effect on the durations of symptoms, signs, and viral positivity.
